SII

Latest News

SII Seeks Govt’s Nod To Manufacture, Stockpile qHPV Vaccine Against Cervical Cancer

The SII will soon seek market authorisation as well as a manufacturing licence from the Drugs Controller General of India (DCGI) for the vaccine.

The application mentions that every year, lakhs of women are diagnosed with cervical cancer and the death ratio is also very high. In India, cervical cancer ranks as the second most frequent cancer among women in the 15-44 age group.

View Post

UP Man Alleges No Antibodies Developed Post Vaccine, Files Complaint Against SII CEO, ICMR Chief

A man from Lucknow, Uttar Pradesh has lodged a complaint against the Serum Institute of India (SII) CEO Adar Poonawala and Dr. Balram Bhargava the head of the Indian Council…

View Post

Serum Institute of India (SII) Has Not Contracted All Its Production Of COVID Vaccine To The Centre Till 25th May 2021

There have been some media reports suggesting that Serum Institute of India (SII) has contracted all its production till 25th May 2021 to the Centre, and therefore till that date…

View Post

Mutant Covid-19 Strain May Force Serum Institute To Alter Vaccine Composition

After the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) expressed concerns about the effectiveness of the vaccine against the South African mutant coronavirus strain, the…

View Post

Spotlight

How Much Will Serum’s Covishield, And Bharat Biotech’s Covaxin Cost?

As the country prepares for the Mega Covid-19 vaccination drive scheduled to start on 16 January, the Ministry of Health of the Union gave a thorough explanation on the Indian…

View Post

First Flight With Covid-19 Vaccines Reaches Delhi

The first batches of Covishield, the vaccine developed by the Serum Institute of India (SII), left Pune to be taken to different parts of the country ahead of the coronavirus…

View Post

Latest News

Covid-19 Vaccine: SII Stockpiles 40-50 Million Doses, To Produce 300 Million Shots By July

The Pune-based vaccine maker, Serum Institute of India (SII) is ready with a stockpile of 40 to 50 million doses of ‘Covishield‘, the COVID-19 vaccine developed by Oxford University and…

View Post

Menu

SII Seeks Govt’s Nod To Manufacture, Stockpile qHPV Vaccine Against Cervical Cancer

UP Man Alleges No Antibodies Developed Post Vaccine, Files Complaint Against SII CEO, ICMR Chief

Serum Institute of India (SII) Has Not Contracted All Its Production Of COVID Vaccine To The Centre Till 25th May 2021

Mutant Covid-19 Strain May Force Serum Institute To Alter Vaccine Composition

How Much Will Serum’s Covishield, And Bharat Biotech’s Covaxin Cost?

First Flight With Covid-19 Vaccines Reaches Delhi

Covid-19 Vaccine: SII Stockpiles 40-50 Million Doses, To Produce 300 Million Shots By July

Epigamia Co-Founder Rohan Mirchandani Passes Away at 42 Due to Cardiac Arrest: Key Risk Factors and Warning Signs for Men in Their 40s

Does the 2022 H5N1 Virus Bind and Replicate Better in the Human Respiratory Tract? Here’s The Truth

Walking Speed Is An Indicator of Metabolic Health in Obese Individuals: Study Reveals

First-Ever Blood-Stage Malaria Vaccine Shows Promising Results in Phase IIb Trial

FDA Moves to Restrict Psychoactive Mushrooms Used in Edibles Amid Growing Concerns

Revolutionary CAR-T Cell Therapy Developed by AIIMS Researchers Offers New Hope for Multiple Myeloma Patients

Severe Strain of Bird Flu Spreading Rapidly: Is India at Risk of Another Pandemic?

India Achieves Significant Progress in Reducing Malaria Cases: WHO Report